- FDA advisory panel met Wednesday to discuss Grail's Galleri blood test for cancer screening.
FDA panel discussed Grail's Galleri blood test for cancer screening, focusing on labeling concerns. Grail stock halted. Analysts see path to approval but cite commercialization hurdles.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.